Filtered By:
Therapy: Cancer Therapy

This page shows you your search results in order of date. This is page number 2.

Order by Relevance | Date

Total 390 results found since Jan 2013.

Fight Aging! Newsletter, January 9th 2023
Fight Aging! publishes news and commentary relevant to the goal of ending all age-related disease, to be achieved by bringing the mechanisms of aging under the control of modern medicine. This weekly newsletter is sent to thousands of interested subscribers. To subscribe or unsubscribe from the newsletter, please visit: https://www.fightaging.org/newsletter/ Longevity Industry Consulting Services Reason, the founder of Fight Aging! and Repair Biotechnologies, offers strategic consulting services to investors, entrepreneurs, and others interested in the longevity industry and its complexities. To find out m...
Source: Fight Aging! - January 8, 2023 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs

A View of Cellular Senescence in Cancer
Cellular senescence is a double-edged sword in the matter of cancer. A cancer cell turned senescent, and thus entered a state of growth arrest, is not a cancer cell that continues to replicate. It secretes pro-growth, pro-inflammatory signals that draw the attention of the immune system. This can be beneficial, helping to defeat a cancer, particularly in the early stages. After a certain point, however, too much cellular senescence aids the cancer in further growth. While it seems clear that senolytic treatments to remove lingering senescent cells are wholly beneficial after a cancer is defeated, it isn't clear that the sa...
Source: Fight Aging! - January 6, 2023 Category: Research Authors: Reason Tags: Daily News Source Type: blogs

Fight Aging! Newsletter, January 2nd 2023
In conclusion, circulating monocytes in older adults exhibit increased expression of activation, adhesion, and migration markers, but decreased expression of co-inhibitory molecules. MERTK Inhibition Increases Bone Density via Increased Osteoblast Activity https://www.fightaging.org/archives/2022/12/mertk-inhibition-increases-bone-density-via-increased-osteoblast-activity/ Bone density results from the balance of constant activity on the part of osteoblasts and osteoclasts, the former building bone, the latter breaking it down. With advancing age, the balance of activity shifts to favor osteoclasts, prod...
Source: Fight Aging! - January 1, 2023 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs

A Look Back at 2022: Progress Towards the Treatment of Aging as a Medical Condition
At the end of 2022, we can reflect on the fact that we are steadily entering a new era of medicine, one in which mechanisms of aging are targeted rather than ignored. It is a profound change, one that will change the shape of a human life and ultimately the human condition by eliminating the greatest sources of suffering and death in the world. Year after year, we see increased funding, ongoing progress towards therapies capable of slowing aging or reversing aspects of aging, and a growing taxonomy of such potential therapies and their target mechanisms. The view of aging in the medical community and public at large...
Source: Fight Aging! - December 30, 2022 Category: Research Authors: Reason Tags: Of Interest Source Type: blogs

Fight Aging! Newsletter, December 19th 2022
In conclusion, p16 deletion or p16 positive cell clearance could be a novel strategy preventing long term HFD-induced skin aging. Association of LDL-Cholesterol with Mortality https://www.fightaging.org/archives/2022/12/association-of-ldl-cholesterol-with-mortality/ Researchers here report on a study of LDL-cholesterol and mortality risk in older people. As they note, data on this topic is conflicted once one moves beyond the matter of cardiovascular disease. Over a lifetime, higher LDL-cholesterol makes it easier to reach the tipping point at which cholesterol deposited in blood vessel walls produces en...
Source: Fight Aging! - December 18, 2022 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs

T Cell Immunotherapy an Improvement Over Checkpoint Inhibition
Researchers here report on the results of a phase III trial of tumor infiltrating leukocyte (TIL) therapy for melanoma. A patient's T cells are multiplied outside the body and then injected, along with chemotherapy beforehand to clear existing T cell populations, and IL-2 delivery afterwards to promote replication of the delivered T cells. It has meaningful side-effects, as do other cancer immunotherapies, but the outcome is an improvement over the present standard approach of checkpoint inhibition for melanoma. Even as better approaches to cancer therapy are in development, such as those based on interference in telomere ...
Source: Fight Aging! - December 14, 2022 Category: Research Authors: Reason Tags: Daily News Source Type: blogs

Fight Aging! Newsletter, November 28th 2022
This study explored whether determining the gain or loss of specific taxa represent a more precise metric of healthy/unhealthy aging than summary microbiome statistics, such as diversity and uniqueness. We analyzed microbiome diversity and four measures of microbiome uniqueness in 21,000 gut microbiomes for their relationship with aging and health. We show that diversity and uniqueness measures are not synonymous; uniqueness is not a uniformly desirable feature of the aging microbiome, nor is it an accurate biomarker of healthy aging. Different measures of uniqueness show different associations with diversity and with mark...
Source: Fight Aging! - November 27, 2022 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs

mTOR in the Enhancement of Cancer Treatment Outcomes via Calorie Restriction
Calorie restriction, and related approaches such as protein restriction, tend to improve the outcomes for cancer patients, making cancers more vulnerable to therapies by reducing the normally rampant replication of cancer cells. Here, researchers explore the role of mTOR signaling in the mechanisms underlying this effect, finding the link between dietary intake of amino acids and mTOR activity in cell growth. Manipulating these mechanisms isn't enough on its own to deal with cancer, but there is a lot to be said for low cost improvements to the odds of success for patients undertaking any form of cancer therapy. R...
Source: Fight Aging! - November 25, 2022 Category: Research Authors: Reason Tags: Daily News Source Type: blogs

Prodrugs As a Useful Approach to Targeting Distinctive Aspects of Cancer Metabolism
The goal of cancer research should be to produce a robust, highly effective universal cancer therapy, or as close to universal as possible. One treatment that can be deployed for every type of cancer, with a very good chance of inducing remission. Attempting to tackle cancer subtypes one by one based on their genetic peculiarities is simply not efficient enough to produce meaningful progress in our lifetimes. Further, most cancers are subject to high mutation rates, and in a sizable fraction of patients will prove to be quite capable of evolving immunity to any therapy that targets a non-essential aspect of cancer biochemi...
Source: Fight Aging! - November 23, 2022 Category: Research Authors: Reason Tags: Medicine, Biotech, Research Source Type: blogs

Extra Hot Nanoparticles for Cancer Therapy
Researchers at Oregon State University created a new type of hyperthermic magnetic nanoparticle that is intended to assist in destroying tumors through localized heating under an alternating magnetic field. Previous iterations of such technologies co...
Source: Medgadget - November 18, 2022 Category: Medical Devices Authors: Conn Hastings Tags: Nanomedicine Oncology Source Type: blogs

Fight Aging! Newsletter, November 14th 2022
In this study, we show that TXNIP is vital for the cell fate choice when cells are challenged by various stress signals. Furthermore, prolonged IGF1 treatment leads to the establishment of a premature senescence phenotype characterized by a unique senescence network signature. Combined IGF1/TXNIP-induced premature senescence can be associated with a typical secretory inflammatory phenotype that is mediated by STAT3/IL-1A signaling. Finally, these mechanistic insights might help with the understanding of basic aspects of IGF1-related pathologies in the clinical setting. Investigating the Ability of Type 2 Diabetes...
Source: Fight Aging! - November 13, 2022 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs

Which chemotherapeutic agent is well known to cause coronary vasospasm?
5-fluorouracil is well known to cause coronary vasospasm. 5-fluorouracil and its orally active prodrug capecitabine are fluoropyrimidines, belonging to the class of antimetabolites used for treatment of malignancies of breast, head and neck tumours and gastrointestinal tumours. Mechanisms for coronary vasospasm Endothelial cell damage with cytolysis and denudation Increased endothelin-1 bioactivity leading to vasoconstriction When high dose infusions are given, coronary vasospasm with angina, arrhythmia or even sudden death can occur in up to 5% of patients. Vascular toxicity occurs generally within 72 hours of the...
Source: Cardiophile MD - November 13, 2022 Category: Cardiology Authors: Johnson Francis Tags: General Cardiology Source Type: blogs

Senescent Cells as a Cancer Vaccine
Researchers here note the discovery that vaccinating mice with senescent cancer cells ensures that the immune system will more aggressively attack a later introduction of cancerous cells. Since we know that most cancer therapies induce senescence in cancerous cells to a fair degree, one has to think that the effectiveness of this approach will diminish as a cancer progresses to form a solid tumor and co-opts the immune system in various ways. Still, it sounds as though it could be a potentially useful after, for example, surgical resection of a tumor, to help reduce the odds that the cancer will reoccur. Scientis...
Source: Fight Aging! - November 9, 2022 Category: Research Authors: Reason Tags: Daily News Source Type: blogs

Magnetic Bacteria Target Tumors
Scientists at ETH Zurich in Switzerland have unveiled a technique that weaponizes bacterial cells against tumors. The approach involves using bacteria called Magnetospirillum that are naturally magnetic by virtue of the iron oxide particles they cont...
Source: Medgadget - November 3, 2022 Category: Medical Devices Authors: Conn Hastings Tags: Medicine Nanomedicine Oncology ETH Zurich ethz Source Type: blogs

AI-Enhanced Prostate Cancer Treatment: Interview with Brittany Berry-Pusey, Co-Founder and COO at Avenda Health
Avenda Health, a medtech company based in Santa Monica, California has developed the FocalPoint ablation system, an AI-powered prostate cancer therapy. The system is designed to provide localized prostate cancer treatment and its AI system equips cli...
Source: Medgadget - November 1, 2022 Category: Medical Devices Authors: Conn Hastings Tags: Exclusive Oncology Urology AvendaHealth Source Type: blogs